View ValuationMedRx 将来の成長Future 基準チェック /06現在、 MedRxの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長11.8%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesReported Earnings • Aug 10Second quarter 2026 earnings released: JP¥5.26 loss per share (vs JP¥3.94 loss in 2Q 2025)Second quarter 2026 results: JP¥5.26 loss per share (further deteriorated from JP¥3.94 loss in 2Q 2025). Net loss: JP¥313.0m (loss widened 56% from 2Q 2025). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.お知らせ • Jul 07MedRx Co., Ltd to Report Q2, 2026 Results on Aug 07, 2026MedRx Co., Ltd announced that they will report Q2, 2026 results on Aug 07, 2026Reported Earnings • May 20First quarter 2026 earnings released: JP¥4.01 loss per share (vs JP¥9.03 loss in 1Q 2025)First quarter 2026 results: JP¥4.01 loss per share (improved from JP¥9.03 loss in 1Q 2025). Net loss: JP¥238.0m (loss narrowed 45% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.New Risk • Mar 05New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Revenue is less than US$1m (JP¥128m revenue, or US$813k). Minor Risks Shareholders have been diluted in the past year (25% increase in shares outstanding). Market cap is less than US$100m (JP¥7.42b market cap, or US$47.2m).Reported Earnings • Feb 16Full year 2025 earnings released: JP¥17.44 loss per share (vs JP¥18.54 loss in FY 2024)Full year 2025 results: JP¥17.44 loss per share. Net loss: JP¥937.0m (loss widened 16% from FY 2024).お知らせ • Feb 13MedRx Co., Ltd, Annual General Meeting, Mar 27, 2026MedRx Co., Ltd, Annual General Meeting, Mar 27, 2026.お知らせ • Dec 27MedRx Co., Ltd to Report Fiscal Year 2025 Results on Feb 13, 2026MedRx Co., Ltd announced that they will report fiscal year 2025 results on Feb 13, 2026分析記事 • Dec 01Is MedRx (TSE:4586) In A Good Position To Invest In Growth?We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...お知らせ • Oct 01MedRx Co., Ltd to Report Q3, 2025 Results on Nov 14, 2025MedRx Co., Ltd announced that they will report Q3, 2025 results on Nov 14, 2025New Risk • Aug 25New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 19% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥1.2b free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Revenue is less than US$1m (JP¥44m revenue, or US$298k). Minor Risks Shareholders have been diluted in the past year (19% increase in shares outstanding). Market cap is less than US$100m (JP¥6.38b market cap, or US$43.3m).New Risk • Aug 14New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -JP¥1.2b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥1.2b free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Revenue is less than US$1m (JP¥44m revenue, or US$300k). Minor Risk Market cap is less than US$100m (JP¥5.18b market cap, or US$35.3m).New Risk • Aug 10New major risk - Revenue sizeThe company makes less than US$1m in revenue. Total revenue: JP¥44m (US$298k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (JP¥44m revenue, or US$298k). Minor Risks Share price has been volatile over the past 3 months (6.7% average weekly change). Market cap is less than US$100m (JP¥3.42b market cap, or US$23.1m).New Risk • Jul 09New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 7.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (7.9% average weekly change). Minor Risks Revenue is less than US$5m (JP¥259m revenue, or US$1.8m). Market cap is less than US$100m (JP¥3.70b market cap, or US$25.2m).お知らせ • Jul 02MedRx Co., Ltd to Report Q2, 2025 Results on Aug 08, 2025MedRx Co., Ltd announced that they will report Q2, 2025 results on Aug 08, 2025お知らせ • Apr 16MedRx Co., Ltd announced that it has received ¥0.8309 million in fundingOn April 16, 2025, MedRx Co., Ltd closed the transaction.New Risk • Apr 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 6.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.1% average weekly change). Shareholders have been diluted in the past year (23% increase in shares outstanding). Revenue is less than US$5m (JP¥257m revenue, or US$1.8m). Market cap is less than US$100m (JP¥2.71b market cap, or US$18.5m).お知らせ • Mar 28MedRx Co., Ltd to Report Q1, 2025 Results on May 09, 2025MedRx Co., Ltd announced that they will report Q1, 2025 results on May 09, 2025お知らせ • Mar 25MedRx Co., Ltd announced that it expects to receive ¥0.8309 million in fundingMEDRx Co., Ltd. announced a private placement to issue 118,700 units 32nd Series of Stock Acquisition Rights at an issue price of ¥7 per right for gross proceeds of ¥830,900 on March 25, 2025. The transaction will include participation from new investor Long Corridor Alpha Opportunities Master Fund. The transaction has been approved by shareholders, expected to close on April 16, 2025. The initial exercise price will be ¥86. The period will be from April 17, 2025 (inclusive) to April 23, 2026 (inclusive). The allocation will be made through a third-party allocation as follows: LCAO 94,960 units MAP 246 23,740 units. The company has disclosed the issue expenses of ¥12,000,000 and net proceeds of ¥1,009,650,900, total amount of payment of ¥1,021,650,900.Reported Earnings • Feb 16Full year 2024 earnings released: JP¥18.54 loss per share (vs JP¥26.80 loss in FY 2023)Full year 2024 results: JP¥18.54 loss per share (improved from JP¥26.80 loss in FY 2023). Revenue: JP¥257.0m (up JP¥228.0m from FY 2023). Net loss: JP¥806.0m (loss narrowed 14% from FY 2023). Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.お知らせ • Feb 14MedRx Co., Ltd, Annual General Meeting, Mar 28, 2025MedRx Co., Ltd, Annual General Meeting, Mar 28, 2025.お知らせ • Jan 03MedRx Co., Ltd to Report Fiscal Year 2024 Results on Feb 14, 2025MedRx Co., Ltd announced that they will report fiscal year 2024 results on Feb 14, 2025分析記事 • Sep 04Here's Why We're Not At All Concerned With MedRx's (TSE:4586) Cash Burn SituationEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...お知らせ • Aug 31MedRx Co., Ltd to Report Q3, 2024 Results on Nov 08, 2024MedRx Co., Ltd announced that they will report Q3, 2024 results on Nov 08, 2024お知らせ • Jun 28MedRx Co., Ltd to Report Q2, 2024 Results on Aug 09, 2024MedRx Co., Ltd announced that they will report Q2, 2024 results on Aug 09, 2024分析記事 • May 13Companies Like MedRx (TSE:4586) Are In A Position To Invest In GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Reported Earnings • May 13First quarter 2024 earnings released: JP¥3.33 loss per share (vs JP¥9.59 loss in 1Q 2023)First quarter 2024 results: JP¥3.33 loss per share (improved from JP¥9.59 loss in 1Q 2023). Net loss: JP¥128.0m (loss narrowed 56% from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.お知らせ • Apr 05MedRx Co., Ltd to Report Q1, 2024 Results on May 10, 2024MedRx Co., Ltd announced that they will report Q1, 2024 results on May 10, 2024お知らせ • Feb 11MedRx Co., Ltd, Annual General Meeting, Mar 28, 2024MedRx Co., Ltd, Annual General Meeting, Mar 28, 2024.お知らせ • Feb 06MedRx Co., Ltd announced that it has received ¥1.9076 million in funding from Evolution Capital Management LLCOn February 5, 2024, MedRx Co., Ltd, closed the transaction.お知らせ • Dec 28MedRx Co., Ltd to Report Fiscal Year 2023 Results on Feb 09, 2024MedRx Co., Ltd announced that they will report fiscal year 2023 results on Feb 09, 2024New Risk • Oct 24New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 54% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥1.3b free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Shareholders have been substantially diluted in the past year (54% increase in shares outstanding). Revenue is less than US$1m (JP¥56m revenue, or US$374k). Minor Risk Market cap is less than US$100m (JP¥5.14b market cap, or US$34.4m).お知らせ • Oct 05MedRx Co., Ltd to Report Q3, 2023 Results on Nov 10, 2023MedRx Co., Ltd announced that they will report Q3, 2023 results on Nov 10, 2023New Risk • Aug 17New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -JP¥1.3b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥1.3b free cash flow). Revenue is less than US$1m (JP¥56m revenue, or US$384k). Minor Risks Share price has been volatile over the past 3 months (5.4% average weekly change). Shareholders have been diluted in the past year (43% increase in shares outstanding). Market cap is less than US$100m (JP¥6.27b market cap, or US$43.0m).Reported Earnings • Aug 12Second quarter 2023 earnings released: JP¥5.60 loss per share (vs JP¥7.52 loss in 2Q 2022)Second quarter 2023 results: JP¥5.60 loss per share. Net loss: JP¥191.0m (loss widened 3.2% from 2Q 2022).お知らせ • Jun 28MedRx Co., Ltd to Report Q2, 2023 Results on Aug 10, 2023MedRx Co., Ltd announced that they will report Q2, 2023 results on Aug 10, 2023Reported Earnings • May 17First quarter 2023 earnings released: JP¥9.59 loss per share (vs JP¥7.97 loss in 1Q 2022)First quarter 2023 results: JP¥9.59 loss per share (further deteriorated from JP¥7.97 loss in 1Q 2022). Net loss: JP¥290.0m (loss widened 48% from 1Q 2022). Revenue is forecast to grow 64% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Pharmaceuticals industry in Japan. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.Reported Earnings • Mar 31Full year 2022 earnings: EPS and revenues miss analyst expectationsFull year 2022 results: JP¥43.80 loss per share. Net loss: JP¥1.11b (loss widened 4.9% from FY 2021). Revenue missed analyst estimates by 82%. Earnings per share (EPS) also missed analyst estimates by 7.4%. Revenue is forecast to grow 61% p.a. on average during the next 3 years, compared to a 4.9% growth forecast for the Pharmaceuticals industry in Japan.Reported Earnings • Feb 12Full year 2022 earnings: EPS and revenues miss analyst expectationsFull year 2022 results: JP¥43.80 loss per share. Net loss: JP¥1.11b (loss widened 4.9% from FY 2021). Revenue missed analyst estimates by 82%. Earnings per share (EPS) also missed analyst estimates by 7.4%. Revenue is forecast to grow 61% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Pharmaceuticals industry in Japan.お知らせ • Feb 12MedRx Co., Ltd, Annual General Meeting, Mar 29, 2023MedRx Co., Ltd, Annual General Meeting, Mar 29, 2023.お知らせ • Dec 28MedRx Co., Ltd to Report Fiscal Year 2022 Results on Feb 10, 2023MedRx Co., Ltd announced that they will report fiscal year 2022 results on Feb 10, 2023Board Change • Nov 16Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 2 experienced directors. 7 highly experienced directors. 1 independent director (6 non-independent directors). Independent External Director Kunio Iwatani was the last independent director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Nov 13Third quarter 2022 earnings released: JP¥10.32 loss per share (vs JP¥9.21 loss in 3Q 2021)Third quarter 2022 results: JP¥10.32 loss per share (further deteriorated from JP¥9.21 loss in 3Q 2021). Net loss: JP¥254.0m (loss widened 25% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.お知らせ • Sep 28MedRx Co., Ltd to Report Q3, 2022 Results on Nov 11, 2022MedRx Co., Ltd announced that they will report Q3, 2022 results on Nov 11, 2022お知らせ • Aug 24MedRx Co., Ltd announced that it expects to receive ¥3.904 million in fundingMedRx Co., Ltd announced a private placement of 61,000 series 24 warrants at a price of ¥64 each for gross proceeds of ¥3,904,000. The series 24 warrants at exercisable at a minimum price of ¥64.Reported Earnings • Aug 12Second quarter 2022 earnings released: JP¥7.52 loss per share (vs JP¥10.61 loss in 2Q 2021)Second quarter 2022 results: JP¥7.52 loss per share (up from JP¥10.61 loss in 2Q 2021). Net loss: JP¥185.0m (loss narrowed 12% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.お知らせ • May 30MedRx Co., Ltd to Report Q2, 2022 Results on Aug 10, 2022MedRx Co., Ltd announced that they will report Q2, 2022 results on Aug 10, 2022Reported Earnings • May 19First quarter 2022 earnings released: JP¥7.97 loss per share (vs JP¥13.32 loss in 1Q 2021)First quarter 2022 results: JP¥7.97 loss per share (up from JP¥13.32 loss in 1Q 2021). Net loss: JP¥196.0m (loss narrowed 25% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings.Board Change • Apr 27Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 2 experienced directors. 7 highly experienced directors. 1 independent director (6 non-independent directors). Independent External Director Kunio Iwatani was the last independent director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Apr 08MedRx Co., Ltd to Report Q1, 2022 Results on May 13, 2022MedRx Co., Ltd announced that they will report Q1, 2022 results on May 13, 2022お知らせ • Feb 12MedRx Co., Ltd, Annual General Meeting, Mar 30, 2022MedRx Co., Ltd, Annual General Meeting, Mar 30, 2022.お知らせ • Jun 04MedRx Co., Ltd announced that it has received ¥552.489 million in funding from Macquarie Bank Limited, Investment ArmOn June 3, 2021, MedRx Co., Ltd (TSE:4586) closed the transaction. The company issued 40 Series 2 Unsecured Bonds at a price of ¥13,750,000 for gross proceeds of ¥550,000,000.お知らせ • May 19MedRx Co., Ltd announced that it expects to receive ¥2.489 million in funding from Macquarie Bank Limited, Investment ArmMedRx Co., Ltd (TSE:4586) announced a private placement of 30,000 series 20 warrants at a price of ¥57 each for gross proceeds of ¥1,710,000 and 19,000 series 21 warrants at a price of ¥41 per share for gross proceeds of ¥779,000? for aggregate gross proceeds of ¥2,489,000 on May 18, 2021. The company will issue securities through third party allotment method to Macquarie Bank Limited, Investment Arm. The series 20 warrants at exercisable at a minimum price of ¥223 and series 21 Warrants for ¥330.Reported Earnings • Apr 04Full year 2020 earnings released: JP¥68.57 loss per share (vs JP¥134 loss in FY 2019)Full year 2020 results: Net loss: JP¥1.11b (loss narrowed 31% from FY 2019). Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings.Reported Earnings • Feb 14Full year 2020 earnings released: JP¥68.57 loss per share (vs JP¥134 loss in FY 2019)Full year 2020 results: Net loss: JP¥1.11b (loss narrowed 31% from FY 2019). Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings.お知らせ • Feb 12MedRx Co., Ltd, Annual General Meeting, Mar 26, 2021MedRx Co., Ltd, Annual General Meeting, Mar 26, 2021.Is New 90 Day High Low • Feb 12New 90-day high: JP¥291The company is up 19% from its price of JP¥244 on 13 November 2020. The Japanese market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 4.0% over the same period.Is New 90 Day High Low • Jan 21New 90-day high: JP¥272The company is up 2.0% from its price of JP¥267 on 23 October 2020. The Japanese market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 15% over the same period.お知らせ • Dec 30MedRx Co., Ltd to Report Fiscal Year 2020 Results on Feb 10, 2021MedRx Co., Ltd announced that they will report fiscal year 2020 results on Feb 10, 2021Is New 90 Day High Low • Dec 09New 90-day low: JP¥228The company is down 23% from its price of JP¥297 on 10 September 2020. The Japanese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 1.0% over the same period.お知らせ • Aug 14MedRx Co., Ltd announced that it has received ¥206.406 million in funding from Japan International Partners LLCOn August 13, 2020, MedRx Co., Ltd (TSE:4586) closed the transaction. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、MedRx は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測TSE:4586 - アナリストの将来予測と過去の財務データ ( )JPY Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数6/30/2026121-859N/AN/AN/A3/31/2026131-746N/AN/AN/A12/31/2025128-937-970-888N/A9/30/2025120-1,255N/AN/AN/A6/30/202544-1,374-1,239-1,239N/A3/31/2025259-1,107N/AN/AN/A12/31/2024257-806-803-803N/A9/30/2024255-581N/AN/AN/A6/30/2024254-512-516-516N/A3/31/202423-770N/AN/AN/A12/31/202329-932-913-913N/A9/30/202379-1,147N/AN/AN/A6/30/202356-1,211-1,252-1,251N/A3/31/202364-1,205N/AN/AN/A12/31/202259-1,111-1,074-1,073N/A9/30/20229-1,017N/AN/AN/A6/30/202210-967-937-936N/A3/31/20222-993N/AN/AN/A12/31/20218-1,059-925-923N/A9/30/2021108-810N/AN/AN/A6/30/2021107-874-878-876N/A3/31/2021122-1,074N/AN/AN/A12/31/2020115-1,114-1,024-985N/A9/30/202016-1,401N/AN/AN/A6/30/2020156-1,462-1,323-1,247N/A3/31/2020151-1,451N/AN/AN/A12/31/2019169-1,616N/A-1,546N/A9/30/2019168-1,523N/AN/AN/A6/30/201928-1,562N/A-1,524N/A3/31/201926-1,442N/AN/AN/A12/31/20188-1,267N/A-1,260N/A9/30/2018187-1,112N/AN/AN/A6/30/2018188-979N/A-1,000N/A3/31/2018180-984N/AN/AN/A12/31/2017198-884N/A-854N/A9/30/201719-975N/AN/AN/A6/30/201730-1,029N/A-987N/A3/31/201731-1,215N/AN/AN/A12/31/201622-1,259N/A-1,215N/A9/30/201624-1,343N/AN/AN/A6/30/201632-1,249N/A-1,142N/A3/31/201632-980N/AN/AN/A12/31/201537-878N/A-789N/A9/30/201536-734N/AN/AN/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 4586の予測収益成長が 貯蓄率 ( 0.9% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 4586の収益がJP市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 4586の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 4586の収益がJP市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 4586の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 4586の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/11 02:18終値2026/08/10 00:00収益2026/06/30年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋MedRx Co., Ltd 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Kiyokazu YamazakiIchiyoshi Research Institute Inc.Dion Stéfan BüchnerPathology Associates Co., Ltd.
Reported Earnings • Aug 10Second quarter 2026 earnings released: JP¥5.26 loss per share (vs JP¥3.94 loss in 2Q 2025)Second quarter 2026 results: JP¥5.26 loss per share (further deteriorated from JP¥3.94 loss in 2Q 2025). Net loss: JP¥313.0m (loss widened 56% from 2Q 2025). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.
お知らせ • Jul 07MedRx Co., Ltd to Report Q2, 2026 Results on Aug 07, 2026MedRx Co., Ltd announced that they will report Q2, 2026 results on Aug 07, 2026
Reported Earnings • May 20First quarter 2026 earnings released: JP¥4.01 loss per share (vs JP¥9.03 loss in 1Q 2025)First quarter 2026 results: JP¥4.01 loss per share (improved from JP¥9.03 loss in 1Q 2025). Net loss: JP¥238.0m (loss narrowed 45% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.
New Risk • Mar 05New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Revenue is less than US$1m (JP¥128m revenue, or US$813k). Minor Risks Shareholders have been diluted in the past year (25% increase in shares outstanding). Market cap is less than US$100m (JP¥7.42b market cap, or US$47.2m).
Reported Earnings • Feb 16Full year 2025 earnings released: JP¥17.44 loss per share (vs JP¥18.54 loss in FY 2024)Full year 2025 results: JP¥17.44 loss per share. Net loss: JP¥937.0m (loss widened 16% from FY 2024).
お知らせ • Feb 13MedRx Co., Ltd, Annual General Meeting, Mar 27, 2026MedRx Co., Ltd, Annual General Meeting, Mar 27, 2026.
お知らせ • Dec 27MedRx Co., Ltd to Report Fiscal Year 2025 Results on Feb 13, 2026MedRx Co., Ltd announced that they will report fiscal year 2025 results on Feb 13, 2026
分析記事 • Dec 01Is MedRx (TSE:4586) In A Good Position To Invest In Growth?We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
お知らせ • Oct 01MedRx Co., Ltd to Report Q3, 2025 Results on Nov 14, 2025MedRx Co., Ltd announced that they will report Q3, 2025 results on Nov 14, 2025
New Risk • Aug 25New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 19% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥1.2b free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Revenue is less than US$1m (JP¥44m revenue, or US$298k). Minor Risks Shareholders have been diluted in the past year (19% increase in shares outstanding). Market cap is less than US$100m (JP¥6.38b market cap, or US$43.3m).
New Risk • Aug 14New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -JP¥1.2b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥1.2b free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Revenue is less than US$1m (JP¥44m revenue, or US$300k). Minor Risk Market cap is less than US$100m (JP¥5.18b market cap, or US$35.3m).
New Risk • Aug 10New major risk - Revenue sizeThe company makes less than US$1m in revenue. Total revenue: JP¥44m (US$298k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (JP¥44m revenue, or US$298k). Minor Risks Share price has been volatile over the past 3 months (6.7% average weekly change). Market cap is less than US$100m (JP¥3.42b market cap, or US$23.1m).
New Risk • Jul 09New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 7.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (7.9% average weekly change). Minor Risks Revenue is less than US$5m (JP¥259m revenue, or US$1.8m). Market cap is less than US$100m (JP¥3.70b market cap, or US$25.2m).
お知らせ • Jul 02MedRx Co., Ltd to Report Q2, 2025 Results on Aug 08, 2025MedRx Co., Ltd announced that they will report Q2, 2025 results on Aug 08, 2025
お知らせ • Apr 16MedRx Co., Ltd announced that it has received ¥0.8309 million in fundingOn April 16, 2025, MedRx Co., Ltd closed the transaction.
New Risk • Apr 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 6.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.1% average weekly change). Shareholders have been diluted in the past year (23% increase in shares outstanding). Revenue is less than US$5m (JP¥257m revenue, or US$1.8m). Market cap is less than US$100m (JP¥2.71b market cap, or US$18.5m).
お知らせ • Mar 28MedRx Co., Ltd to Report Q1, 2025 Results on May 09, 2025MedRx Co., Ltd announced that they will report Q1, 2025 results on May 09, 2025
お知らせ • Mar 25MedRx Co., Ltd announced that it expects to receive ¥0.8309 million in fundingMEDRx Co., Ltd. announced a private placement to issue 118,700 units 32nd Series of Stock Acquisition Rights at an issue price of ¥7 per right for gross proceeds of ¥830,900 on March 25, 2025. The transaction will include participation from new investor Long Corridor Alpha Opportunities Master Fund. The transaction has been approved by shareholders, expected to close on April 16, 2025. The initial exercise price will be ¥86. The period will be from April 17, 2025 (inclusive) to April 23, 2026 (inclusive). The allocation will be made through a third-party allocation as follows: LCAO 94,960 units MAP 246 23,740 units. The company has disclosed the issue expenses of ¥12,000,000 and net proceeds of ¥1,009,650,900, total amount of payment of ¥1,021,650,900.
Reported Earnings • Feb 16Full year 2024 earnings released: JP¥18.54 loss per share (vs JP¥26.80 loss in FY 2023)Full year 2024 results: JP¥18.54 loss per share (improved from JP¥26.80 loss in FY 2023). Revenue: JP¥257.0m (up JP¥228.0m from FY 2023). Net loss: JP¥806.0m (loss narrowed 14% from FY 2023). Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
お知らせ • Feb 14MedRx Co., Ltd, Annual General Meeting, Mar 28, 2025MedRx Co., Ltd, Annual General Meeting, Mar 28, 2025.
お知らせ • Jan 03MedRx Co., Ltd to Report Fiscal Year 2024 Results on Feb 14, 2025MedRx Co., Ltd announced that they will report fiscal year 2024 results on Feb 14, 2025
分析記事 • Sep 04Here's Why We're Not At All Concerned With MedRx's (TSE:4586) Cash Burn SituationEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
お知らせ • Aug 31MedRx Co., Ltd to Report Q3, 2024 Results on Nov 08, 2024MedRx Co., Ltd announced that they will report Q3, 2024 results on Nov 08, 2024
お知らせ • Jun 28MedRx Co., Ltd to Report Q2, 2024 Results on Aug 09, 2024MedRx Co., Ltd announced that they will report Q2, 2024 results on Aug 09, 2024
分析記事 • May 13Companies Like MedRx (TSE:4586) Are In A Position To Invest In GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Reported Earnings • May 13First quarter 2024 earnings released: JP¥3.33 loss per share (vs JP¥9.59 loss in 1Q 2023)First quarter 2024 results: JP¥3.33 loss per share (improved from JP¥9.59 loss in 1Q 2023). Net loss: JP¥128.0m (loss narrowed 56% from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.
お知らせ • Apr 05MedRx Co., Ltd to Report Q1, 2024 Results on May 10, 2024MedRx Co., Ltd announced that they will report Q1, 2024 results on May 10, 2024
お知らせ • Feb 11MedRx Co., Ltd, Annual General Meeting, Mar 28, 2024MedRx Co., Ltd, Annual General Meeting, Mar 28, 2024.
お知らせ • Feb 06MedRx Co., Ltd announced that it has received ¥1.9076 million in funding from Evolution Capital Management LLCOn February 5, 2024, MedRx Co., Ltd, closed the transaction.
お知らせ • Dec 28MedRx Co., Ltd to Report Fiscal Year 2023 Results on Feb 09, 2024MedRx Co., Ltd announced that they will report fiscal year 2023 results on Feb 09, 2024
New Risk • Oct 24New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 54% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥1.3b free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Shareholders have been substantially diluted in the past year (54% increase in shares outstanding). Revenue is less than US$1m (JP¥56m revenue, or US$374k). Minor Risk Market cap is less than US$100m (JP¥5.14b market cap, or US$34.4m).
お知らせ • Oct 05MedRx Co., Ltd to Report Q3, 2023 Results on Nov 10, 2023MedRx Co., Ltd announced that they will report Q3, 2023 results on Nov 10, 2023
New Risk • Aug 17New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -JP¥1.3b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥1.3b free cash flow). Revenue is less than US$1m (JP¥56m revenue, or US$384k). Minor Risks Share price has been volatile over the past 3 months (5.4% average weekly change). Shareholders have been diluted in the past year (43% increase in shares outstanding). Market cap is less than US$100m (JP¥6.27b market cap, or US$43.0m).
Reported Earnings • Aug 12Second quarter 2023 earnings released: JP¥5.60 loss per share (vs JP¥7.52 loss in 2Q 2022)Second quarter 2023 results: JP¥5.60 loss per share. Net loss: JP¥191.0m (loss widened 3.2% from 2Q 2022).
お知らせ • Jun 28MedRx Co., Ltd to Report Q2, 2023 Results on Aug 10, 2023MedRx Co., Ltd announced that they will report Q2, 2023 results on Aug 10, 2023
Reported Earnings • May 17First quarter 2023 earnings released: JP¥9.59 loss per share (vs JP¥7.97 loss in 1Q 2022)First quarter 2023 results: JP¥9.59 loss per share (further deteriorated from JP¥7.97 loss in 1Q 2022). Net loss: JP¥290.0m (loss widened 48% from 1Q 2022). Revenue is forecast to grow 64% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Pharmaceuticals industry in Japan. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.
Reported Earnings • Mar 31Full year 2022 earnings: EPS and revenues miss analyst expectationsFull year 2022 results: JP¥43.80 loss per share. Net loss: JP¥1.11b (loss widened 4.9% from FY 2021). Revenue missed analyst estimates by 82%. Earnings per share (EPS) also missed analyst estimates by 7.4%. Revenue is forecast to grow 61% p.a. on average during the next 3 years, compared to a 4.9% growth forecast for the Pharmaceuticals industry in Japan.
Reported Earnings • Feb 12Full year 2022 earnings: EPS and revenues miss analyst expectationsFull year 2022 results: JP¥43.80 loss per share. Net loss: JP¥1.11b (loss widened 4.9% from FY 2021). Revenue missed analyst estimates by 82%. Earnings per share (EPS) also missed analyst estimates by 7.4%. Revenue is forecast to grow 61% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Pharmaceuticals industry in Japan.
お知らせ • Feb 12MedRx Co., Ltd, Annual General Meeting, Mar 29, 2023MedRx Co., Ltd, Annual General Meeting, Mar 29, 2023.
お知らせ • Dec 28MedRx Co., Ltd to Report Fiscal Year 2022 Results on Feb 10, 2023MedRx Co., Ltd announced that they will report fiscal year 2022 results on Feb 10, 2023
Board Change • Nov 16Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 2 experienced directors. 7 highly experienced directors. 1 independent director (6 non-independent directors). Independent External Director Kunio Iwatani was the last independent director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Nov 13Third quarter 2022 earnings released: JP¥10.32 loss per share (vs JP¥9.21 loss in 3Q 2021)Third quarter 2022 results: JP¥10.32 loss per share (further deteriorated from JP¥9.21 loss in 3Q 2021). Net loss: JP¥254.0m (loss widened 25% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.
お知らせ • Sep 28MedRx Co., Ltd to Report Q3, 2022 Results on Nov 11, 2022MedRx Co., Ltd announced that they will report Q3, 2022 results on Nov 11, 2022
お知らせ • Aug 24MedRx Co., Ltd announced that it expects to receive ¥3.904 million in fundingMedRx Co., Ltd announced a private placement of 61,000 series 24 warrants at a price of ¥64 each for gross proceeds of ¥3,904,000. The series 24 warrants at exercisable at a minimum price of ¥64.
Reported Earnings • Aug 12Second quarter 2022 earnings released: JP¥7.52 loss per share (vs JP¥10.61 loss in 2Q 2021)Second quarter 2022 results: JP¥7.52 loss per share (up from JP¥10.61 loss in 2Q 2021). Net loss: JP¥185.0m (loss narrowed 12% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.
お知らせ • May 30MedRx Co., Ltd to Report Q2, 2022 Results on Aug 10, 2022MedRx Co., Ltd announced that they will report Q2, 2022 results on Aug 10, 2022
Reported Earnings • May 19First quarter 2022 earnings released: JP¥7.97 loss per share (vs JP¥13.32 loss in 1Q 2021)First quarter 2022 results: JP¥7.97 loss per share (up from JP¥13.32 loss in 1Q 2021). Net loss: JP¥196.0m (loss narrowed 25% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings.
Board Change • Apr 27Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 2 experienced directors. 7 highly experienced directors. 1 independent director (6 non-independent directors). Independent External Director Kunio Iwatani was the last independent director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Apr 08MedRx Co., Ltd to Report Q1, 2022 Results on May 13, 2022MedRx Co., Ltd announced that they will report Q1, 2022 results on May 13, 2022
お知らせ • Feb 12MedRx Co., Ltd, Annual General Meeting, Mar 30, 2022MedRx Co., Ltd, Annual General Meeting, Mar 30, 2022.
お知らせ • Jun 04MedRx Co., Ltd announced that it has received ¥552.489 million in funding from Macquarie Bank Limited, Investment ArmOn June 3, 2021, MedRx Co., Ltd (TSE:4586) closed the transaction. The company issued 40 Series 2 Unsecured Bonds at a price of ¥13,750,000 for gross proceeds of ¥550,000,000.
お知らせ • May 19MedRx Co., Ltd announced that it expects to receive ¥2.489 million in funding from Macquarie Bank Limited, Investment ArmMedRx Co., Ltd (TSE:4586) announced a private placement of 30,000 series 20 warrants at a price of ¥57 each for gross proceeds of ¥1,710,000 and 19,000 series 21 warrants at a price of ¥41 per share for gross proceeds of ¥779,000? for aggregate gross proceeds of ¥2,489,000 on May 18, 2021. The company will issue securities through third party allotment method to Macquarie Bank Limited, Investment Arm. The series 20 warrants at exercisable at a minimum price of ¥223 and series 21 Warrants for ¥330.
Reported Earnings • Apr 04Full year 2020 earnings released: JP¥68.57 loss per share (vs JP¥134 loss in FY 2019)Full year 2020 results: Net loss: JP¥1.11b (loss narrowed 31% from FY 2019). Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings.
Reported Earnings • Feb 14Full year 2020 earnings released: JP¥68.57 loss per share (vs JP¥134 loss in FY 2019)Full year 2020 results: Net loss: JP¥1.11b (loss narrowed 31% from FY 2019). Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings.
お知らせ • Feb 12MedRx Co., Ltd, Annual General Meeting, Mar 26, 2021MedRx Co., Ltd, Annual General Meeting, Mar 26, 2021.
Is New 90 Day High Low • Feb 12New 90-day high: JP¥291The company is up 19% from its price of JP¥244 on 13 November 2020. The Japanese market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 4.0% over the same period.
Is New 90 Day High Low • Jan 21New 90-day high: JP¥272The company is up 2.0% from its price of JP¥267 on 23 October 2020. The Japanese market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 15% over the same period.
お知らせ • Dec 30MedRx Co., Ltd to Report Fiscal Year 2020 Results on Feb 10, 2021MedRx Co., Ltd announced that they will report fiscal year 2020 results on Feb 10, 2021
Is New 90 Day High Low • Dec 09New 90-day low: JP¥228The company is down 23% from its price of JP¥297 on 10 September 2020. The Japanese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 1.0% over the same period.
お知らせ • Aug 14MedRx Co., Ltd announced that it has received ¥206.406 million in funding from Japan International Partners LLCOn August 13, 2020, MedRx Co., Ltd (TSE:4586) closed the transaction.